Pancreatic Cancer Research

ResearcherVanderbilt UniversityNo recent work listed

Emily W. Chan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9458-3080; OpenAlex author ID A5088841234. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 4

  1. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000377↗
  2. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Last author DOI 10.1002/cam4.208↗
  3. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. Co-author DOI 10.1200/jco.2013.53.5617↗
  4. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Co-author PMID 23077684↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan D. Berlin · 4 shared papers, 2012–2018 · strength 0.25
  2. Dana Backlund Cardin · 2 shared papers, 2014–2018 · strength 0.12
  3. Laura Williams Goff · 2 shared papers, 2014–2018 · strength 0.12
  4. Ramya Thota · 1 shared paper, 2018 · strength 0.09
  5. Chakravarthy Ab · 1 shared paper, 2012 · strength 0.03
  6. Alexander A. Parikh · 1 shared paper, 2012 · strength 0.03
  7. Nipun B. Merchant · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.